Concepedia

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

Cornedine J. de Gooijer, Vincent van der Noort, Jos A. Stigt, Bonne Biesma, Robin Cornelissen, Nico van Walree, Robbert C. van Heemst, Magdolen Youssef-El Soud, Harry J.M. Groen, A.J. Staal-van den Brekel,

The Lancet Respiratory Medicine · 2021 · 50 citations · 18 references

DOIFull text

Open access

Concepts

References

18

No Adjustments Are Needed for Multiple Comparisons

Kenneth J. Rothman · Epidemiology · 1990 · 5.8K citations

, , +15

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3.1K citations

, , +13

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Zielinski et al. · The Lancet · 2009 · 1.1K citations · Full text

, , +14

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Gérard Zalcman, Julien Mazières, J. Margery et al. · The Lancet · 2015 · 972 citations

, , +10

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Dean A. Fennell, Keith M. Kerr, Paul E. Van Schil et al. · Annals of Oncology · 2015 · 420 citations · Full text

, , +14